Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Research and Development in the Physical, Engineering, and Life Sciences (541710)
SIC:
Commercial Physical and Biological Research (8731)
Contact Information
Investor Relations and Media Contact
Sutro Biopharma
Emily White
Investor Relations and Communications Advisor
T: 650-823-7681
ewhite@sutrobio.com
Company Contact
Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080